Kura Oncology (KURA) Expected to Release Earnings on Thursday

Kura Oncology (NASDAQ:KURA) is projected to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.8773) per share and revenue of $20.1630 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 12:30 PM ET.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The firm had revenue of $18.27 million during the quarter, compared to analyst estimates of $25.97 million. On average, analysts expect Kura Oncology to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kura Oncology Trading Up 2.0%

NASDAQ:KURA opened at $9.19 on Tuesday. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14. The business’s 50-day simple moving average is $10.15 and its 200-day simple moving average is $9.27. The stock has a market capitalization of $815.80 million, a PE ratio of -2.74 and a beta of 0.38. Kura Oncology has a fifty-two week low of $5.45 and a fifty-two week high of $12.49.

Insider Activity

In other news, insider Mollie Leoni sold 84,929 shares of the business’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $9.82, for a total transaction of $834,002.78. Following the completion of the sale, the insider directly owned 182,345 shares of the company’s stock, valued at $1,790,627.90. The trade was a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently made changes to their positions in the company. Suvretta Capital Management LLC boosted its stake in shares of Kura Oncology by 5.7% during the 4th quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company’s stock worth $89,099,000 after acquiring an additional 459,422 shares in the last quarter. Vanguard Group Inc. raised its stake in Kura Oncology by 2.2% during the 3rd quarter. Vanguard Group Inc. now owns 5,468,522 shares of the company’s stock valued at $48,396,000 after purchasing an additional 120,197 shares during the last quarter. State Street Corp raised its position in shares of Kura Oncology by 47.5% during the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after acquiring an additional 1,587,959 shares during the last quarter. AQR Capital Management LLC increased its holdings in Kura Oncology by 36.6% during the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after buying an additional 820,020 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its position in Kura Oncology by 101.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after purchasing an additional 1,121,228 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research report on Thursday, May 28th. Jefferies Financial Group set a $24.00 price target on Kura Oncology in a report on Thursday, May 28th. Sanford C. Bernstein set a $24.00 price target on Kura Oncology in a report on Monday, June 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th. Finally, Lake Street Capital started coverage on Kura Oncology in a report on Tuesday, April 14th. They issued a “buy” rating and a $23.00 target price for the company. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and an average target price of $25.46.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.